Original paper
P060 Rituximab as third line therapy in IgG4-Related Disease: experience from a multi-centre cohort
Published: Sep 1, 2021
Abstract
Introduction
Immunoglobulin G4-Related Disease (IgG4RD) is a rare multi-organ fibro-inflammatory immune-mediated disorder that has a predilection for the pancreas and bile ducts, leading to organ damage and failure, and an increased risk of malignancy. B cells play a crucial role in disease pathogenesis and disease relapse. Rituximab (anti-CD20 chimeric monoclonal antibody) has received UK NICE approval for third-line therapy for...Paper Details
Title
P060 Rituximab as third line therapy in IgG4-Related Disease: experience from a multi-centre cohort
Published Date
Sep 1, 2021
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History